Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections

Antimicrob Agents Chemother. 2014 Sep;58(9):5598-601. doi: 10.1128/AAC.02435-13. Epub 2014 Jun 30.

Abstract

Ninety-four patients infected with carbapenem-resistant Acinetobacter baumannii were randomized to receive colistin alone or colistin plus fosfomycin for 7 to 14 days. The patients who received combination therapy had a significantly more favorable microbiological response and a trend toward more favorable clinical outcomes and lower mortality than those who received colistin alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01297894.).

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology
  • Acinetobacter Infections / mortality
  • Acinetobacter baumannii / drug effects*
  • Aged
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Carbapenems / therapeutic use
  • Colistin / adverse effects
  • Colistin / therapeutic use*
  • Cross Infection / drug therapy
  • Cross Infection / microbiology
  • Drug Resistance, Multiple, Bacterial
  • Drug Therapy, Combination
  • Female
  • Fosfomycin / adverse effects
  • Fosfomycin / therapeutic use*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Pilot Projects
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • Fosfomycin
  • Colistin

Associated data

  • ClinicalTrials.gov/NCT01297894